Related Articles
Integrin β1‑mediated acquired gefitinib resistance in non‑small cell lung cancer cells occurs via the phosphoinositide 3-kinase‑dependent pathway
Increased MIR31HG lncRNA expression increases gefitinib resistance in non-small cell lung cancer cell lines through the EGFR/PI3K/AKT signaling pathway
Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line
Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Overexpression of CTEN is associated with gefitinib resistance in non‑small cell lung cancer